Directors Report: As previously advised, the royalties from the...

Directors Report:

As previously advised, the royalties from the sales of the Blood Collection Device are slower than originally budgeted but are continuing to grow and we and Sol Millennium remain confident regarding the future sales. All existing patents have been maintained while the Company is actively reviewing a number of new technologies including next-generation needle product innovations that will complement the existing medical device portfolio and build future value in the Company. A small placement and a successful share purchase plan raised some necessary capital to progress the growth of the Company.
------------------------

It lacks the mood, tempo and enthusiasm of pre-CR, and It certainly doesn't adhere to the proposed strategy of ramping up communication's and building a community around Medigard.
Things take time, so no need for unrealistic short term expectations from share holders. But please spare us the rhetoric of ramping up communication etc, etc if you don't intend to follow through with it. That directors report is seriously lacking.